Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.31 |
| ▸ | NPC1 | O15118 | 3/20 | 0.31 |
| ▸ | RAB9A | P51151 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3407715 | 0.90 | SMN1; SMN2 (0.36) | HDAC4SMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL3404268 | 0.87 | HPGD (0.34) | HDAC4SMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL3405134 | 0.87 | EPHX2 (0.33) | SMN1; SMN2NPC1RAB9AALDH1A1KMT2A | |
| SCHEMBL3404648 | 0.86 | HDAC4 (0.34) | HDAC4MAPK1ATMTSHR | |
| SCHEMBL3407820 | 0.85 | HDAC4 (0.34) | HDAC4SMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL3402021 | 0.83 | MEN1 (0.31) | NPC1KMT2A | |
| SCHEMBL3407676 | 0.82 | TAS2R14 (0.36) | SMN1; SMN2NPC1RAB9AALDH1A1MAPK14 | |
| SCHEMBL3407823 | 0.81 | ADORA2A (0.39) | RAB9AALDH1A1MAPK14MAPK1KDM4E | |
| SCHEMBL3403825 | 0.80 | KDM4E (0.33) | SMN1; SMN2ALDH1A1MAPK14KDM4EKMT2A | |
| SCHEMBL3406303 | 0.79 | MLYCD (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1370260-B1 | AZOLES AS MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2010-11-24 | — | — | EP | claimed |
| US-20040092503-A1 | Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-05-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092503-A1 | Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators | ME1, ME3, ME2 | HDAC4 1331/4885SMN1; SMN2 3627/4885NPC1 833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.